Ravidasvir

Ravidasvir (PPI-668) is an NS5A inhibitor in clinical trials for chronic hepatitis C Genotype-4.[1]

Clinical trial results were announced in Nov 2015.[2]

References

  1. ↑ A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
  2. ↑ Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4
This article is issued from Wikipedia - version of the Tuesday, February 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.